



Press Release:

Astellas and ASKA Enter into License Agreement for AKP-002

Tokyo, October 19, 2010—Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and ASKA Pharmaceutical Co., Ltd. ("ASKA"; headquarters: Tokyo; CEO: Takashi Yamaguchi) announced today that they have entered into an exclusive worldwide license agreement to develop, manufacture and commercialize AKP-002 being developed by ASKA.

AKP-002 is discovered and developed by ASKA and currently under development in phase I for the treatment for functional symptoms of benign prostate hyperplasia.

Under the terms of the agreement Astellas is granted the worldwide exclusive right to develop, manufacture and commercialize AKP-002 whereas ASKA retains an option to co-promote the product in Japan. Astellas will pay ASKA up-front and development milestone payments and royalties on the sales.

Astellas has a treatment for overactive bladder Vesicare[®] and a treatment for functional symptoms of benign prostate hyperplasia Harnal[®] in the urology therapeutic area and expects this agreement to further contribute to the treatment for urological diseases by entering into this agreement.

Urology is one of ASKA's strategic areas, and ASKA is marketing Prostal[®] for the treatment of benign prostate hypertrophy and prostate cancer as the main product in this therapeutic area. ASKA retains co-promotion right for AKP-002 in Japan and will strengthen the marketing activity in the urology area.

The impact of this agreement on Astellas' the current fiscal year (from April 1, 2010 to March 31, 2011) financial forecast and the later will be immaterial. Whereas, the impact of this agreement on ASKA's current fiscal year (from April 1, 2010 to March 31, 2011) financial forecast and the later will be announced later on a timely manner.

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 15,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology & Infectious Diseases, Neuroscience, DM complications & Metabolic Diseases and Oncology. For more information on Astellas Pharma Inc., please visit our website at <http://www.astellas.com/en>.

About ASKA

ASKA Pharmaceutical Co., Ltd. located in Tokyo, Japan, is a research and development (R&D) oriented company, which contributes to the society by developing and providing innovative pharmaceutical products with concentrating its management resources to the specific therapeutic areas. Additional information on ASKA Pharmaceutical Co., Ltd. is available through its corporate website, <http://www.aska-pharma.co.jp/english/index.html>.

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com/en
ASKA Pharmaceutical Co., Ltd. Corporate Communications Tel: +81-3-5484-8366 Fax: +81-3-5484-8351 http://www.aska-pharma.co.jp/english/